BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 27170453)

  • 21. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H
    Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.
    Chen YK; Hou HA; Tang JL; Jhuang JY; Lai YJ; Lee MC; Kuo YY; Chou WC; Liu CY; Lin CW; Chuang SS; Chen CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    PLoS One; 2015; 10(3):e0119831. PubMed ID: 25794001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
    Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
    Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focal Adhesion Kinase as a Potential Target in AML and MDS.
    Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
    Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
    Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B
    Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature.
    Mossner M; Hopfer O; Nowak D; Baldus CD; Neumann U; Kmetsch A; Benlasfer O; John T; Perka C; Thiel E; Hofmann WK
    Exp Hematol; 2010 Aug; 38(8):661-5. PubMed ID: 20399247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
    Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome.
    Gao L; Saeed A; Golem S; Zhang D; Woodroof J; McGuirk J; Ganguly S; Abhyankar S; Lin TL; Cui W
    Int J Lab Hematol; 2021 Feb; 43(1):99-109. PubMed ID: 32812335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
    Grövdal M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Wallvik J; Tangen JM; Oberg G; Jacobsen SE; Hokland P; Porwit A; Hellström-Lindberg E
    Clin Cancer Res; 2007 Dec; 13(23):7107-12. PubMed ID: 18056190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
    Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
    J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome].
    Wang W; Wang HY; Zhao HX; Cui ZG; Li GL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):470-3. PubMed ID: 17605847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and
    Martin-Cabrera P; Jeromin S; Perglerovà K; Haferlach C; Kern W; Haferlach T
    Haematologica; 2017 Apr; 102(4):e125-e128. PubMed ID: 28057736
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.